XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 745,740 $ 581,329 $ 2,106,602 $ 1,773,019
ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 71,029 13,812 144,849 88,533
Product        
Disaggregation of Revenue [Line Items]        
Revenue 733,867 568,266 2,073,811 1,739,390
Marketed by Company | Products excluding ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 662,838 554,454 1,928,962 1,650,857
Marketed by Company | Products excluding ALDURAZYME | United States        
Disaggregation of Revenue [Line Items]        
Revenue 235,515 194,745 655,963 553,184
Marketed by Company | Products excluding ALDURAZYME | Europe        
Disaggregation of Revenue [Line Items]        
Revenue 191,017 168,784 607,755 512,910
Marketed by Company | Products excluding ALDURAZYME | Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 111,908 81,524 274,920 224,716
Marketed by Company | Products excluding ALDURAZYME | Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 124,398 109,401 390,324 360,047
Marketed by Sanofi | ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue $ 71,029 $ 13,812 $ 144,849 $ 88,533